Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024 [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024. Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (aSyn), LRKK2, and GBA pathologies. Aggregated aSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration. The panel will discuss the use of biomarkers to define PD and differentiate it from other synucleinophaties, the course, the progression, and staging of patients. The forum will feature a line-up of international discussants including Fabrizio Stocchi, MD, PhD (University San Raffaele Roma
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders [Yahoo! Finance]Yahoo! Finance
- Annovis Bio CEO Maria Maccecchini Issues Letter to StockholdersGlobeNewswire
- Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market [Seeking Alpha]Seeking Alpha
- Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects [Seeking Alpha]Seeking Alpha
- Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question [Seeking Alpha]Seeking Alpha
ANVS
Earnings
- 8/14/23 - Beat
ANVS
Sec Filings
- 5/2/24 - Form 8-K
- 5/1/24 - Form 8-K
- 5/1/24 - Form 424B5
- ANVS's page on the SEC website